CLINICAL CHARACTERISTICS RELATED WITH HIGH ON-TREATMENT PLATELET REACTIVITY RECEIVING CLOPIDOGREL MEASURED BY THROMBELASTOGRAPHY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION  by Hou, Xu-Min
Chronic CAD/Stable Ischemic Heart Disease
E1405
JACC March 27, 2012
Volume 59, Issue 13
CLINICAL CHARACTERISTICS RELATED WITH HIGH ON-TREATMENT PLATELET REACTIVITY RECEIVING 
CLOPIDOGREL MEASURED BY THROMBELASTOGRAPHY IN PATIENTS UNDERGOING PERCUTANEOUS 
CORONARY INTERVENTION
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 9:30 a.m.-10:30 a.m.
Session Title: How to Pick Your Antiplatelet Therapy
Abstract Category: 2. Chronic CAD/Stable Ischemic Heart Disease: Clinical
Presentation Number: 1197-39
Authors: Xu-Min Hou, Shanghai Chest Hospital, Shanghai, People’s Republic of China
Background: Antiplatelet therapy with clopidogrel and aspirin is the current standard of care for patients undergoing PCI. However, recurrent 
ischemic event occurrence during dual antiplatelet therapy, including stent thrombosis, remains a major concern. We sought to determine whether 
clinical characteristics will be associated with high on-treatment platelet reactivity receiving clopidogrel measured by thrombelastography.
Methods: A total of 362 consecutive patients undergoing non-emergent PCI were enrolled in this prospective observational study. A 300mg 
clopidogrel loading dose was administered on the day before procedure (>12h). Blood samples were analysed using a computerised TEG analyser for 
platelet aggregation. The cut points for high on treatment platelet reactivity (HPR) were defined as ≥60% ADP-induced aggregation with 2-μmol ADP. 
All patients below the cut point were defined as exhibiting normal on-treatment platelet reactivity (NPR).
Results: The prevalence of HPR was 33% measured by TEG. There were more female patients in HPR group than in NPR group (41.7% vs 22.3%, 
P=0.007). The prevalence of diabetes mellitus was higher in HPR group (41.7% vs 24.2%, P=0.0024), as well as the level of fasting plasma glucose 
(8.0±3.8mmol/L vs 6.7±2.7mmol/L, P=0.018) and HbA1C (7.4±1.7% vs 6.6±1.3%, P=0.007). Meanwhile, elevated plasma triglyceride was common 
in HPR group than in NPR group (2.5±0.9mmol/L vs 1.9±0.3mmol/L, P=0.019). Patients with HPR exhibited a higher level of cardiac enzyme 
including CK-MB (3.1±1.3ng/mL vs 1.8±1.6ng/mL, P=0.013) and troponin I (0.9±0.3ng/mL vs 0.2±0.4ng/mL, P=0.01). Moreover, the prevalence of 
current smoking was higher in HPR group (12.3% vs 2.6%, P=0.012).
Conclusions: Despite adequate pretreatment with clopidogrel, 30% patients undergoing non-emergent PCI exhibited high on-treatment ADP-
induced platelet aggregation measured by thrombelastography. We found that current smoking, high level of HbA1C and TnI, and female gender 
independently predicted the risk of HPR.
